Medium impact
Radioimmunoscintigraphy (Monoclonal Antibody Imaging) With Indium 111 Capromab Pendetide for Prostate Cancer
Blue Cross & Blue Shield of Mississippi·Identified Jun 20, 2026
HCPCS A9507 is officially defined as "Indium in-111 capromab pendetide, diagnostic, per study dose, up to 10 millicuries." HCPCS A9507 is referenced in 1 tracked payer policy change from Blue Cross & Blue Shield of Mississippi. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS A9507 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Related
Get alerts for changes like this
Save a search and receive a daily digest whenever a new policy change matches your filters.